Testing BTM-3566 for lymphoma that has returned
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental drug called BTM-3566 in people with a type of lymphoma that has come back or not responded to previous treatments. The goal is to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a type of lymphoma called mature B cell lymphoma that has returned or not responded to treatment.
- Your lymphoma can be measured on scans.
- You are able to take care of yourself (ECOG score 0-2).
- You are expected to live at least 3 more months.
- You agree to use birth control during the study and for 90 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, BTM-3566, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
This early-stage trial tests a new drug called GSK5926371 in adults whose B-cell lymphoma (a blood cancer) has come back or stopped responding to previous treatments. The study aims to find out if this drug is safe and whether it can help shrink the cancer.
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
This trial tests a new drug called JMT601 for people with a type of B-cell lymphoma that came back or didn't respond to at least two previous treatments. The drug targets a protein on the cancer cells to help your immune system fight the disease.
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
This trial tests an experimental drug called SCTB35 for people with relapsed or refractory B-cell non-Hodgkin lymphoma that is CD20-positive. It aims to find a safe dose and see how well it works.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.